Abstract: To study the antiobesity function of the chitosan compounds (chitosan, white kidney bean extracts, grape seed extract and selenium-enriched yeast), except the blank control group rats, the rest rats were feed with high fat diet for 2 weeks to establish fatty animal models, and then the successful model of the rats were randomly divided into model group, orlistat group (48 mg/kg), chitosan compounds high (0.812 g/kg), middle (0.406 g/kg) and low (0.203 g/kg) dose groups. After 6 weeks of administration, the changes of weight, Lee's index, liver index, fat index, the contents of serum triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), leptin, adiponectin, liver malondialdehyde (MDA), and the activity of serum alanine aminotransferase (ALT), glutamic oxaloacetylase (AST), liver superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) were detected. Compared with the rats in model group, the high dose of chitosan compounds could significantly lower the weight, liver index, the contents of serum TG and TC, the activity of AST and ALT (P<0.05), remarkably lower the Lee's index, fat index, the contents of the serum LDL-C, leptin, and the liver MDA (P<0.01), remarkably improve the contents of the serum adiponectin and the activity of liver SOD (P<0.01) and significantly improve the activity of liver GSH-Px (P<0.05). The middle dose of chitosan compounds (0.406 g/kg) could significantly lower the weight, Lee's index, liver index, fat index, the contents of the serum TG, TC, leptin and liver MDA, the activity of serum ALT and AST (P<0.05), and remarkably lower the contents of LDL-C (P<0.01), and significantly improve the contents of adiponectin and the activity of liver SOD (P<0.05). Chitosan compounds had the antiobesity function, and its mechanism would be related to regulating the level of hormone related to fat metabolism, accelerating lipid metabolism and reducing oxidative damage.